Perrigo awarded US FDA's final approval for AB Rated generic Zovirax Cream 5%
7 February 2019 -

Health and wellness company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of the final approval from the US Food and Drug Administration (FDA) for its AB rated Abbreviated New Drug Application referencing Zovirax Cream, 5% (acyclovir cream, 5%) against herpes viruses.

The company added the generic Zovirax Cream, 5% (acyclovir cream, 5%) was developed in collaboration with Sol-Gel Technologies Ltd (NASDAQ:SLGL).

Following the US FDA's approval, the company anticipates launching Zovirax Cream, 5% (acyclovir cream, 5%) this month.

For the 12 months ending December 2018, the annual market sales were approximately USD92m as measured by IQVIA, concluded the company